Drugs-Induction Flashcards

1
Q

rATG: mechanisms of T cell depletion

A
  1. Complement-dependent cytotoxicity

2. Opsonization / phagocytosis via macrophages

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

rATG: secondary effects besides T cell depletion

A
  1. Induction of B cell apoptosis
  2. Induction of Treg cells
  3. Modulation of adhesion molecules/cell trafficking
  4. Antibody-dependent cellular cytotoxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

rATG is indicated for induction for which organs?

A

Kidney txp only

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

rATG - PI recommended dosing for induction

A

1.5 mg/kg x4 - 7 days

FIRST DOSE PRIOR TO REPERFUSION (reduce DGF)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

rATG - PI recommended duration of infusion

A

1st dose: minimum of 6 hours

Subsequent doses: minimum 4 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

rATG - PI recommended pre-medication

A

Corticosteroids, APAP, and/or an antihistamine 1 hour prior to each infusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

rATG - PI recommended dose modifications for WBC and platelet

A

WBC 2-3: 1/2 dose
WBC <2: Consider stopping
Plt 50-75: 1/2 dose
Plt <50: Consider stopping

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

rATG contraindications

A

History of allergy or anaphylactic reaction to rabbit proteins or to any product excipients, or who have active acute or chronic infections that contraindicate any additional immunosuppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

rATG - How supplied, reconstitution, BUD, Filter

A

Supplied: 10 mL vial with 25 mg lyophilized product
Reconstitute: 5mL SWFI
BUD: 24 hours @ RT
Filter: 0.22 micrometer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

eATG is indicated for induction for which organs?

A

Kidney txp only

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

eATG - PI recommended dosing for induction

A

10-15 mg/kg daily x14d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

eATG - PI recommended duration of infusion

A

At least 4 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

eATG - How supplied, BUD, Filter

A

Supplied: 50 mg/mL concentrate
BUD: 24 hours @ RT
Filter: 0.2 to 1.0 micron

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Alemtuzumab: Mechanism of depletion

A

Anti-CD52 monoclonal antibody (CD52 is a membrane glycoprotein on T cells, B cells, and innate cells)

  1. Complement-dependent cytotoxicity
  2. Antibody-dependent cellular cytotoxicity
  3. Induction of apoptosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Alemtuzumab: indications in SOT

A

None

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Alemtuzumab: IV infusion instructions

A
Vial = 30 mg/mL (1 mL vial)
2 hours
Mix in 100 mL bag of NS or D5W
BUD: 8 hours
Incompatible with PVC
17
Q

Alemtuzumab: Premedication

A

Benadryl, APAP 30 minutes prior to each infusion

18
Q

Basiliximab: MOA

A

IL-2R Antagonist; competitively inhibits IL-2 mediated activation of lymphocytes by binding with high affinity to IL-2Ra on activated lymphocytes

19
Q

Basiliximab: indications in SOT

A

Kidney txp recipients receiving cyclosporine and corticosteroids

20
Q

Basiliximab: Administration per PI

A

Central or peripheral
Infusion: 20 - 30 minutes (bolus may be associatd with n/v, local rxn)
Dilute to 50 mL with NS or D5W
BUD: 24 hr fridge; 4 hr RT

21
Q

Basiliximab: Dosing per PI

A
Adults: 20 mg 
 - Dose 1 within 2 hours prior to txp surgery
- Dose 2: 4 days after txp
Peds: (same schedule as adults)
 - <35 kg: 10 mg
 - >35 kg: 20 mg
22
Q

Basiliximab: Concentration for effect

A

Serum conc of 0.2 mcg/mL saturates IL-2R

23
Q

Antithymocyte globulin: central vs peripheral administraiton

A

PI: “high-flow vein”
IRL: peripheral (heparin + hydrocort + inc volume) or central

24
Q

Kidney txp: most common induction agent

A

T-cell depleting agent&raquo_space;> IL2RA > None

25
Q

Liver txp: most common induction agent

A

None&raquo_space;> IL2RA > T-cell depleting

26
Q

Pancreas txp: most common induction agent

A

T-cell depleting

27
Q

Intestine txp: most common induction agent

A

T-cell depleting > None > IL2RA

28
Q

Heart txp: most common induction agent

A

None&raquo_space; IL2RA > T-cell depleting

29
Q

Lung txp: most common induction agent

A

IL-2RA&raquo_space; None > T cell depleting

30
Q

Kidney txp: eATG vs rATG Efficacy

A

rATG = lower rates of BPAR and improved graft & patient survival

31
Q

Kidney txp: efficacy data supports which agent for high risk candidate?

A

T cell depleting agent (rATG or alemtuzumab)

32
Q

Liver txp: data supports which agent for induction?

A

Data sucks. Induction may reduce rates of rejection without clear effect on long term patient or graft outcomes

33
Q

Heart txp: data supports which agent?

A

Data sucks. Benefit with induction is unclear - may reduce rejection rates but long-term effects inconsistent. IL2RA may provide similar long term benefits compared with rATG. Consider in sensitized patients.

34
Q

Lung txp: data supports which agent?

A

Data sucks. Depleting therapy appears to reduce rejection with trade off of infection. IL2RA may be preferred though effect not clear.

35
Q

Intestinal txp: data supports which agent?

A

Alemtuzumab = lowest risk of rejection

rATG + rituximab = next lowest risk of rejection BUT lower risk of infxn compared with alemtuzumab